on Polyphor AG (isin : CH0106213793)
Spexis AG Granted Extension for 2023 Annual Report Submission
On April 30, 2024, Spexis AG announced that it has received an extension from SIX Exchange Regulation AG for the publication of its 2023 annual report. The new deadline for the submission of the report is set for May 31, 2024. Spexis AG, a biopharmaceutical company, cited ongoing legal discussions and negotiations with its major creditor as reasons for the delay.
The decision from SIX specifies that Spexis must publish these details in accordance with the rules of ad hoc publicity by the end of April 30, 2024. Furthermore, it warns that trading of its shares could be suspended if the report is not submitted by the updated deadline.
Spexis has vowed to publish unaudited financial statements by the end of May 2024 amidst ongoing discussions with its primary creditor SPRIM Global Investments regarding certain enforcement actions, which the company claims are wrongful. This situation has directly impacted the audit process and timeline.
R. H.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Polyphor AG news